Roughly 30,000 Americans are diagnosed with multiple myeloma each year—a rare but serious cancer of the plasma cells. Historically treated with chemotherapy, patients often faced recurring disease and…
Kidney cancer affects over 80,000 Americans annually, with renal cell carcinoma as the dominant type. Benjamin R. Lee, MD, MBA, outlines current AUA guideline recommendations, including when to…
Rajdeep Mysore, MD discusses melanoma, the most dangerous type of skin cancer. Originating from melanocytes, the color-producing cells in the skin, melanomas often appear as black or brown…
This presentation delves into the pathophysiology of CML, highlighting its progression from the chronic phase through the accelerated phase to the blast phase.
Emma, a person who has IgA nephropathy, discusses her experience with diagnosis and treatment. She also discusses the importance of communication with medical professionals and she recommends avoiding…
Helen Rizos, PhD focuses on the clinical value of cell-free DNA in the management of melanoma. It highlights how circulating tumor DNA can be predictive and prognostic for…
Clarissa Tio, MD, a nephrologist at the University of Mississippi, moderates a discussion between Ariana Barton, a patient living with IgA nephropathy and a patient advocate, Joshua Samuels,…
Jonathan Barratt, MD, consultant nephrologist and professor of renal medicine, University of Leicester and John Walls Renal Unit, Leicester, provides a comprehensive overview of IgA nephropathy. Professor Barratt…
Dr. Richard Lafayette, founder and director of the Glomerular Disease Center at Stanford University Medical Center, discusses the prevalence and impact of IgA nephropathy, the most common primary…
This video discusses IgA nephropathy (IgAN), a kidney disease where proteins from the immune system build up in the kidney filters, causing inflammation and potential damage. It details…
The CARE1 pragmatic clinical trial was designed to determine the optimal treatment combination for patients with metastatic kidney cancer, using a specific biomarker. The trial, funded by the…
